Yap, Taz and Areg Expression in Eighth Cranial Nerve Schwannoma
暂无分享,去创建一个
L. Denaro | L. Giacomelli | A. Fassina | R. Stramare | A. Martini | D. d'Avella | R. Cappellesso | G. Marioni | A. Mazzoni | E. Zanoletti | C. Faccioli | E. Fasanaro
[1] A. Rutjes,et al. Circulating Tumor Markers: A Guide to Their Appropriate Clinical Use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 2) , 2017, The International journal of biological markers.
[2] A. Rutjes,et al. Circulating Tumor Markers: A Guide to their Appropriate Clinical use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 1) , 2016, The International journal of biological markers.
[3] L. Giacomelli,et al. The prognostic role of the epithelial–mesenchymal transition markers E‐cadherin and Slug in laryngeal squamous cell carcinoma , 2015, Histopathology.
[4] H. Ohgaki,et al. Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas , 2015, Journal of neuropathology and experimental neurology.
[5] P. Hogendoorn,et al. Tumor Biology of Vestibular Schwannoma: A Review of Experimental Data on the Determinants of Tumor Genesis and Growth Characteristics , 2015, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[6] A. Fassina,et al. YAP immunoreactivity is directly related to pilomatrixoma size and proliferation rate , 2015, Archives of Dermatological Research.
[7] M. Fassan,et al. Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas. , 2014, The American journal of pathology.
[8] Q. Wang,et al. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells , 2014, Molecular medicine reports.
[9] P. Hupé,et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. , 2014, Neuro-oncology.
[10] Li-juan Wang,et al. Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma , 2014, Journal of immunology research.
[11] Xaralabos Varelas,et al. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease , 2014, Development.
[12] Daniel T. Montoro,et al. Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis , 2014, The EMBO journal.
[13] S. Dupont,et al. Molecular Pathways Molecular Pathways : YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis , 2013 .
[14] K. Guan,et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.
[15] N. Yang,et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin , 2012, Cell cycle.
[16] A. Mazzoni,et al. Hearing preservation surgery in acoustic neuroma: long-term results , 2012, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.
[17] P. Cayé-Thomasen,et al. Epidemiology and natural history of vestibular schwannomas. , 2012, Otolaryngologic clinics of North America.
[18] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[19] A. Mazzoni,et al. Hearing preservation surgery in acoustic neuroma. Slow progress and new strategies , 2011, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.
[20] D. Pan,et al. The hippo signaling pathway in development and cancer. , 2010, Developmental cell.
[21] J. Kissil,et al. Merlin in organ size control and tumorigenesis: Hippo versus EGFR? , 2010, Genes & development.
[22] Li Li,et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.
[23] Jianmin Zhang,et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway , 2009, Nature Cell Biology.
[24] Jiandie D. Lin,et al. TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.
[25] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[26] G. Feldmann,et al. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.
[27] Jianmin Zhang,et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.
[28] P. Cayé-Thomasen,et al. The Natural History of Vestibular Schwannoma , 2006, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[29] M. Yaffe,et al. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. , 2005, The Biochemical journal.
[30] J. Kanzaki,et al. New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. , 2003, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[31] M. Yaffe,et al. TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins , 2000, The EMBO journal.